Cargando…

Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation

INTRODUCTION: Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galanopoulos, A., Tsiolka, E., Ntounas, P., Mpelimpasakis, D., Karakoutas, D., Sidiropoulos, N., Mpougiouklis, I., Kyziridis, K., Papalexi, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471128/ http://dx.doi.org/10.1192/j.eurpsy.2021.895

Ejemplares similares

The impact of dose on the real-world effectiveness of vortioxetine in outpatients with mdd in greece
por: Papalexi, E., et al.
Publicado: (2021)

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
por: Papalexi, Eugenia, et al.
Publicado: (2022)

The Impact of Negative Symptoms and Neurocognition on Functioning in MDD and Schizophrenia
por: Quek, Yue Feng, et al.
Publicado: (2021)

Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
por: Montano, C Brendan, et al.
Publicado: (2022)

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
por: Ng, Chong Guan, et al.
Publicado: (2023)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)
por: Chokka, Pratap, et al.
Publicado: (2019)

Early improvement of painful symptoms in MDD: is there an association in achieving remission?
por: Bär, Karl-Jürgen
Publicado: (2007)

Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2021)

Evolution of symptoms with antipsychotic treatment in schizophrenic outpatients in Greece: the GRACE Study
por: Karadima, Dimitra, et al.
Publicado: (2010)

The prognosis and changes of regional brain gray matter volume in MDD with gastrointestinal symptoms
por: Liu, Penghong, et al.
Publicado: (2019)

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
por: Mahableshwarkar, Atul R., et al.
Publicado: (2015)

Study design of VGOAL-J: an observational, prospective cohort study to assess effectiveness of vortioxetine on goal achievement and work productivity in patients with MDD in Japan
por: Watanabe, K., et al.
Publicado: (2022)

Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy—Case Series
por: Siwek, Marcin, et al.
Publicado: (2022)

Vortioxetine-induced manic mood switch in patient with previously unknown bipolar disorder
por: Sobreira, Gonçalo, et al.
Publicado: (2017)

Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes
por: Di Nicola, Marco, et al.
Publicado: (2023)

PS83. Impact of Vortioxetine on Functional Capacity in MDD Patients with Subjective Cognitive Dysfunction: A Post-hoc Analysis of the University of California San Diego Performance-Based Skills Assessment
por: Jacobson, William, et al.
Publicado: (2016)

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
por: Yuan, Hsinsung, et al.
Publicado: (2019)

Polygenic analyses show important differences between MDD symptoms collected using PHQ9 and CIDI-SF
por: Huang, Lianyun, et al.
Publicado: (2023)

Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study
por: Levada, Oleg A., et al.
Publicado: (2020)

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2022)

Why is Diagnosing MDD Challenging?
Publicado: (2016)

Panic Disorder Induced by the Coronavirus Disease Pandemic in a Patient with Organic Mood Disorder Successfully Treated with Vortioxetine
por: Yoshimura, Reiji, et al.
Publicado: (2020)

French version validation of the psychotic symptom rating scales (PSYRATS) for outpatients with persistent psychotic symptoms
por: Favrod, Jerome, et al.
Publicado: (2012)

Mood symptoms in cervical dystonia: Relationship with motor symptoms and quality of life
por: Rafee, Shameer, et al.
Publicado: (2023)

S103. ASSESSING MOOD SYMPTOMS IN PSYCHOSIS: EXAMINING DIFFERENCES IN MOOD SYMPTOM PRESENTATION AMONGST RACIAL AND ETHNIC MINORITIES WITH PSYCHOSIS
por: Bolden, Khalima, et al.
Publicado: (2020)

POSTPARTUM GAD IS A RISK FACTOR FOR POSTPARTUM MDD: THE COURSE AND LONGITUDINAL RELATIONSHIPS OF POSTPARTUM GAD AND MDD
por: Prenoveau, Jason, et al.
Publicado: (2013)

Digital biomarkers of mood disorders and symptom change
por: Jacobson, Nicholas C., et al.
Publicado: (2019)

Dissociating breathlessness symptoms from mood in asthma
por: Harrison, Olivia K., et al.
Publicado: (2021)

From MDD concepts to experiments and illustrations
por: Babau, Jean-Philippe, et al.
Publicado: (2006)

Basic symptoms in offspring of parents with mood and psychotic disorders
por: Zwicker, Alyson, et al.
Publicado: (2019)

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016)

The neurocognitive profile of post‐traumatic stress disorder (PTSD), major depressive disorder (MDD), and PTSD with comorbid MDD
por: Koopowitz, Sheri‐Michelle, et al.
Publicado: (2021)

Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in Rheumatoid Arthritis Patients in Greece: Analysis of the Greek Cohort of SENSE study
por: Sidiropoulos, Prodromos, et al.
Publicado: (2022)

MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS
por: Russo, Manuela, et al.
Publicado: (2015)

Could the mood disorder symptoms can be predict by metabolic disturbances?
por: Rog, J., et al.
Publicado: (2022)

The impact of alcohol hangover symptoms on cognitive and physical functioning, and mood
por: van Schrojenstein Lantman, Marith, et al.
Publicado: (2017)

Assessment of Symptoms in Cancer Patients Undergoing Chemotherapy in Northern Greece
por: Lavdaniti, Maria
Publicado: (2015)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l4k2j3q5bnqthr22u3use2ltop